{"id":"NCT01831791","sponsor":"GlaxoSmithKline","briefTitle":"A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia","officialTitle":"Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-14","primaryCompletion":"2014-07-19","completion":"2014-07-19","firstPosted":"2013-04-15","resultsPosted":"2015-03-12","lastUpdate":"2018-06-20"},"enrollment":120,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alopecia"],"interventions":[{"type":"DRUG","name":"Dutasteride 0.5 mg","otherNames":[]}],"arms":[{"label":"Dutasteride Arm","type":"EXPERIMENTAL"}],"summary":"This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of 0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia types III vertex, IV and V per the Norwood-Hamilton classification. The study consists of a Screening Phase (3 weeks prior to Baseline) and a Treatment Phase (52 weeks). A subject who completes the full course of study treatment and the final study visit (Week 52; Visit 7) will be considered as study completion.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)","timeFrame":"From Baseline (Week 0) until Week 52","effectByArm":[{"arm":"Dutasteride 0.5 mg","deltaMin":64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":23},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":["26893187"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":120},"commonTop":["Nasopharyngitis","Erectile dysfunction","Libido decreased"]}}